Select Page
AI-ML-enabled-real-world-evidence(RWE)-analytics

AI/ML-enabled real-world evidence analytics

Augment value for pharma and medical devices by analyzing real-world evidence (RWE) across the product life cycle.

Real-world evidence

As the focus on value-based pricing increased, the importance of RWE rises to support clinical inferences on treatment efficacies. The information from electronic health records (EHR) and electronic medical records (EMR) along with other patient treatment records is compelling to guide companies, physicians, and the managed care ecosystem to deliver truly benefitting patient outcomes. Razor-sharp data and analytics capabilities are crucial for harvesting real-world data (RWD) and delivering evidence-based assessments across the healthcare value continuum.

Axtria’s experience with RWD processing and management, along with its AI/ML RWE models help healthcare stakeholders generate and demonstrate value and meet growing evidence generation requirements.

Read Report / HEOR value demonstration and evidence generation challenges

Drivers for evidence-based demonstrations across the product life cycle

Pre-launch

Launch and scale

Loss-of-exclusivity (LOE)
Pre-launch
Pre-launch icon
  • Unmet needs and disease burden
  • Patient recruitment
  • Understand the standard of care
  • Clinical trial design
Launch & scale
Launch and Scale icon
  • Patient safety
  • Product comparative effectiveness
  • Patient adherence
  • Prescribing patterns
  • Differentiation in sub-populations
  • Long-term clinical outcomes
  • Target population implications
Loss-of-exclusivity (LOE)
Loss-of-exclusivity icon
  • Effects of switching on outcomes
  • Usage differences
  • Differentiate with or vs. protected formulation
  • For payers to deliver cost-effective care coverage and value for patients’ money.
  • For providers to identify better ways to manage patient health.
  • For life sciences organizations to make better decisions related to pre-launch, market access, and commercialization.

Read Blog / Implications from HEOR and RWE models for biopharmaceutical commercial analytics

Read Blog / Unveiling The Key Trends And Topics: Axtria’s Insights From ISPOR 2023

Axtria’s RWE/HEOR solutions span across the healthcare value spectrum

RWD Expertise

RWD EXPERTISE Icon1

Patient claims

RWD EXPERTISE Icon2

EHR/EMR data

RWD EXPERTISE Icon3

Lab results

RWD EXPERTISE Icon4

Patient registries

RWD EXPERTISE Icon5

Adverse event reporting

RWD EXPERTISE Icon6

Patient-powered research networks (PPRN)

RWE/HEOR Applications Across Domains

RWE-HEOR APPLICATIONS Icon1

Study design

RWE-HEOR APPLICATIONS Icon2

Epidemiology analysis

RWE-HEOR APPLICATIONS Icon3

Real-world comparative analysis

RWE-HEOR APPLICATIONS Icon4

Patient compliance and persistence

RWE-HEOR APPLICATIONS Icon5

Market access and reimbursement strategy

RWE-HEOR APPLICATIONS Icon6

Biomarker analysis

RWE-HEOR APPLICATIONS Icon7

Burden of disease analysis

RWE-HEOR APPLICATIONS Icon8

Drug utilization and patient profiling

RWE-HEOR APPLICATIONS Icon9

Publication and HTA submission support

RWE-HEOR APPLICATIONS Icon10

Budget impact analysis

Read Blog / Quantifying the economic burden of inadequate symptom control among patients with IBS-D

Read Article / RWE In Clinical Trials – Market Trends And Use Cases